| Pharmacology |
|
| Administration route | ORAL |
| Organism | Pinus maritima (PINACEAE) |
| Citation | BELCARO,G: CESARONE,MR: ERRICHI,S:ZULLI,C: ERRICHI,BM: VINCIGUERRA,G: LEDDA,A: DI RENZO,A: STUARD,S: DUGALL,M: PELLEGRINI,L: ERRICHI,S: GIZZI,G: IPPOLITO,E: RICCI,A: CACCHIO,M: CIPOLLONE,G: RUFFINI,I: FANO,F: HOSOI,M: ROHDEWALD,P:. (2008). TREATMENT OF OSTEOARTHRITIS WITH PYCNOGENOL®. THE SVOS (SAN VALENTINO OSTEO-ARTHROSIS STUDY). EVALUATION OF SIGNS, SYMPTOMS, PHYSICAL PERFORMANCE AND VASCULAR ASPECTS. 22() |
| Amount utilized | |
| Compound isolated | |
| Disease | DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY OF 100 MG PYCNOGENOL®
DAILY (ORAL CAPSULES) IN A 3 MONTH STUDY IN PATIENTS WITH OSTEOARTHRITIS (OA). OA SYMPTOMS WERE EVALUATED
BY WOMAC SCORES, MOBILITY BY RECORDING THEIR WALKING PERFORMANCE (TREADMILL). TREATMENT (77 PATIENTS) AND
PLACEBO GROUP (79) WERE COMPARABLE FOR AGE, SEX DISTRIBUTION, WOMAC SCORES, WALKING DISTANCES AND USE OF
ANTIINFLAMMATORY DRUGS. THE GLOBAL WOMAC SCORE DECREASED BY 56% (P < 0.05) IN THE TREATMENT GROUP
VERSUS 9.6% IN THE PLACEBO GROUP. WALKING DISTANCE IN THE TREADMILL TEST WAS PROLONGED FROM 68 M AT THE START
TO 198 M AFTER 3 MONTHS TREATMENT (P < 0.05), UNDER PLACEBO, FROM 65 M TO 88 M (NS). THE USE OF DRUGS
DECREASED BY 58% IN THE TREATMENT GROUP (P < 0.05) VERSUS 1% UNDER PLACEBO. GASTROINTESTINAL COMPLICATIONS
DECREASED BY 63% IN THE TREATMENT GROUP, BUT ONLY 3% UNDER PLACEBO. OVERALL, TREATMENT COSTS WERE REDUCED
SIGNIFICANTLY COMPARED WITH PLACEBO. FOOT EDEMA WAS PRESENT IN 76% OF THE PATIENTS OF THE TREATMENT GROUP
AT INCLUSION AND IN 79% OF THE CONTROLS. AFTER 3 MONTHS EDEMA DECREASED IN 79% OF PYCNOGENOL PATIENTS
(P < 0.05) VS 1% IN CONTROLS. IN CONCLUSION, PYCNOGENOL OFFERS AN OPTION FOR REDUCTION OF TREATMENT COSTS AND
SIDE EFFECTS BY SPARING ANTIINFLAMMATORY DRUGS. |
| Dose amount | 100 MG |
| Number | 0 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | DAY |
| Dose expression | DOSE |
| Extract | TYPE EXT NOT STATED |